{
  "report_rows": [
    {
      "kpi": "Q2 billings",
      "prediction": "BEAT",
      "answer": "pred ~$2.22B vs. cons $2.13B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.94B vs. cons $1.89B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 non-GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.79 vs. cons $0.75",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 revenue",
      "prediction": "BETTER",
      "answer": "guide ~$7.94B vs. cons $7.81B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 billings",
      "prediction": "BETTER",
      "answer": "guide ~$9.15B vs. cons $9.05B (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY2026 non-GAAP EPS",
      "prediction": "BETTER",
      "answer": "guide ~$3.23 vs. cons $3.16 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 revenue",
      "prediction": "BETTER",
      "answer": "guide ~$1.98B vs. cons $1.95B (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 4.8,
  "day1_confidence": "LOW",
  "day5_residual_pct": 3.6,
  "day5_path": "STABILIZE",
  "day5_rationale": "The Q2 beat and FY2026 raise should lift estimates, but implied H2 revenue of roughly $4.15B versus consensus near $4.07B provides only modest out-period upside; elevated valuation limits additional rerating after the initial move.",
  "day5_confidence": "LOW"
}